GoodRx price target lowered to $5.50 from $9.50 at DA Davidson

DA Davidson lowered the firm’s price target on GoodRx to $5.50 from $9.50 but keeps a Buy rating on the shares. The company’s Q3 results and Q4 guide were good enough, but the unexpected and very conservative outlook for 2024 took down the stock, the analyst tells investors in a research note. The firm adds however that if newer programs perform well into year-end and beyond, there’s strong upside to GoodRx shares.